Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $210.42 USD
Change Today +1.03 / 0.49%
Volume 1.5M
VRX On Other Exchanges
Symbol
Exchange
Toronto
Mexico
Frankfurt
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

Earnings & Estimates Summary - VALEANT PHARMACEUTICALS INTE (VRX)

Valeant Pharmaceuticals International, Inc. to Report Q1, 2015 on Apr 29, 2015
CapIQ 04/29/2015 12:00 PM ET
Valeant Pharmaceuticals International, Inc. to Report Q4, 2014 on Feb 23, 2015
CapIQ 04/29/2015 12:00 PM ET
Valeant Pharmaceuticals International, Inc. to Report Q3, 2014 on Oct 20, 2014
CapIQ 04/29/2015 12:00 PM ET

2013 revenues at Valeant Pharmaceuticals International, Inc. totaled $5.8B USD, while annual earnings equaled $6.24 per share.

Quarterly Earnings & Estimates - VALEANT PHARMACEUTICALS INTE (VRX)

Actuals vs. Estimates for VALEANT PHARMACEUTICALS INTE VRX

Valeant Pharmaceuticals International, Inc.'s Quarterly Earnings

Valeant Pharmaceuticals International, Inc. reported 2nd quarter 2014 earnings of $1.91 per share on 08/2/2014.

Annual Earnings & Estimates - VALEANT PHARMACEUTICALS INTE (VRX)

Actuals vs. Estimates for VALEANT PHARMACEUTICALS INTE VRX

Valeant Pharmaceuticals International, Inc.'s Annual Earnings

Valeant Pharmaceuticals International, Inc. reported annual 2013 earnings of $6.24 per share on 03/1/2014.

Quarterly Revenues - VALEANT PHARMACEUTICALS INTE (VRX)

Actuals vs. Estimates for VALEANT PHARMACEUTICALS INTE VRX

Valeant Pharmaceuticals International, Inc.'s Quarterly Revenues

Valeant Pharmaceuticals International, Inc. had 2nd quarter 2014 revenues of $2.0B USD. This missed the $2.0B USD consensus estimate of the 17 analysts following the company. This was 86.3% above the prior year's 2nd quarter results.

Annual Revenues - VALEANT PHARMACEUTICALS INTE (VRX)

Actuals vs. Estimates for VALEANT PHARMACEUTICALS INTE VRX

Valeant Pharmaceuticals International, Inc.'s Annual Revenues

Valeant Pharmaceuticals International, Inc. had revenues for the full year 2013 of $5.8B USD. This was 62.7% above the prior year's results.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $210.42 USD +1.03

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,948 JPY -27.50
Mylan NV $76.06 USD +2.37
Perrigo Co PLC $192.89 USD -8.74
Sun Pharmaceutical Industries Ltd 947.40 INR +5.40
Teva Pharmaceutical Industries Ltd $64.41 USD +1.16
View Industry Companies
 

Industry Analysis

VRX

Industry Average

Valuation VRX Industry Range
Price/Earnings 78.3x
Price/Sales 8.5x
Price/Book 13.2x
Price/Cash Flow 30.0x
TEV/Sales 6.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.